TempraMed Signs Exclusive Distribution Agreement with DayMed Qatar, Expanding Gulf Region Commercial Footprint
- Written by Reporters
Approximately US$500,000 in potential purchases over the initial three-year term, based on VIVI Cap minimum volumes; agreement targets Qatar's high-prevalence diabetes market through hospital and pharmacy channels
Highlights- Exclusive distribution arrangement in Qatar with an initial 36-month term, intended to support local registration,...

